MERIT MEDICAL SYSTEMS INC — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 45/100
What the filing says
Merit Medical reported Q3 2026 revenue of $416.2M (8.4% YoY growth, 9% organic constant currency), with GAAP EPS of $0.70 (up 51%) and non-GAAP EPS of $1.12 (up 22%). The company raised full-year 2026 revenue guidance to $1.635–$1.642B and non-GAAP EPS guidance to $4.33–$4.37 (13–14% growth). Separately, on October 13, 2026, Merit acquired all remaining equity of Solo Pace, Inc. (temporary pacing technology for TAVR procedures) for ~$45M in cash, after previously holding ~18% ownership from $5M prior investments.
Why this rating
Strong Q3 results and upward guidance revision are favorable, but modest relative to $5.4B market cap (~0.8% of sales). Solo Pace acquisition is small ($45M, ~0.8% of cap), projected immaterial to FY2026, slightly accretive 2027+. Mixed routine developments.
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.